FDA Approves Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for Subcutaneous Use inGeneralized Myasthenia Gravis
June 20, 2023FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Minimal ResidualDisease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
June 21, 2023June 20, 2023 - AGEPHA Pharma USA, LLC, has announced that, following a Priority Review, the U.S. Food and Drug Administration (FDA) has approved Lodoco® as the first anti-inflammatory atheroprotective cardiovascular treatment demonstrated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.
AGEPHA Pharma anticipates that Lodoco, which can reduce the risk of cardiac events in patients with established cardiovascular diseases by 31% on top of standard of care, will be available for prescription in the second half of 2023. The company has not determined an exact price but is planning to offer a patient assistance program to ensure that patients who otherwise could not afford the Lodoco will be able to have access to the drug.